Moderna Data Finds Covid Vaccine is Over 90% Effective Against Virus 6 Months After 2nd Shot

Posted on

More data is revealing that getting the Covid-19 vaccine is the wise decision as Moderna just revealed its vaccine is more than 90% effective against the virus six months after the second shot.

Citing updated data from its phase three clinical trial, the company announced this week that its Covid-19 vaccine was more than 90% effective at protecting against Covid and more than 95% effective against severe disease up to six months after the second dose.

This includes cases through April 9. The company had evaluated over 900 cases, including more than 100 severe cases.

Modern is inching closer to filing its request for full U.S. approval for its vaccine. Full approval requires a more rigorous review process to show the shot is safe and effective for its intended use.

The company can begin marketing the shots directly to consumers and selling them to individuals and private companies in the U.S. once it gains full approval.

The vaccine is currently authorized for emergency use by the Food and Drug Administration for people who are age 18 and older, and the agency can revoke the emergency use authorization, or EUA, at any time.

“I think it is fair to estimate that they will both have decent efficacy for many months beyond this,” said Dr. Isaac Bogoch, an infectious disease specialist who has sat on several drug data and safety monitoring boards,

Moderna is still evaluating its vaccine in people ages 17 and younger and a testing trial with participants aged 12 to 17 are fully enrolled. There are around 3,000 participating in the trial in the U.S.

Disclaimer: We have no position in any of the companies mentioned and have not been compensated for this article.